Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intranasal ELI 200 Human Abuse Liability (HAL) trial: A double-blind, randomised 5-way crossover study

Next Previous
Trial Profile

Intranasal ELI 200 Human Abuse Liability (HAL) trial: A double-blind, randomised 5-way crossover study

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELI 200 (Primary) ; ELI 200 (Primary) ; Oxycodone
  • Indications Opioid-related disorders
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Elite Pharmaceuticals

    • Most Recent Events

    • 09 May 2016 Pharmacodynamic data assessing the abuse potential will be presented at the American Pain Society 35th Annual Scientific Meeting 2016, according to an Elite Pharmaceuticals media release.
    • 17 Sep 2014 New trial record
    • 09 Sep 2014 Primary endpoint has been met. (the peak effect (E max ) for Drug Liking).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top